Home / Lifestyle / Health & Fitness / Article / Australia leads first human trial of one-time gene editing therapy to halve bad cholesterol

Australia leads first human trial of one-time gene editing therapy to halve bad cholesterol

The trial tested CTX310, a one-time CRISPR-Cas9 gene-editing therapy that uses fat-based particles to carry CRISPR editing tools into the liver, switching off the ANGPTL3 gene

  • WhatsAppBookmarkBookmark
Listen to this article :
Image for representational purpose only. Photo Courtesy: File pic

Image for representational purpose only. Photo Courtesy: File pic

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol and triglycerides in people with difficult-to-treat lipid disorders. 

The trial tested CTX310, a one-time CRISPR-Cas9 gene-editing therapy that uses fat-based particles to carry CRISPR editing tools into the liver, switching off the ANGPTL3 gene. Turning off this gene lowers LDL (bad) cholesterol and triglycerides, two blood fats linked to heart disease, according to a statement released Monday by Australia's Monash University.

Read Next Story
Nagaland University researchers unlock medicinal secrets of rare Meghalaya plant›

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All